Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

In Vivo Anti-BCMA/CD19 CAR-T Cell Treatment for B Cell-Mediated Autoimmune Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAlexander J. NajibiDWDenise WongJWJeff Wood

Discussion

Loading...

Member takes

Overview

Preclinical development of tandem CAR-T cells shows promise in treating autoimmune disorders, indicating new therapeutic avenues.

Key Points

  • The aim is to develop an effective CAR-T cell treatment that targets both CD19-positive and CD19-negative B cells for autoimmune diseases like SLE.
  • Engineering of a tandem CAR targeting both BCMA and CD19 using a lentiviral vector
  • In vitro testing of CAR-T cells for cytotoxicity and cytokine release against BCMA/CD19-expressing cell lines
  • Establishment of SLE and B cell lymphoma mouse models to evaluate in vivo efficacy of CAR-T cell treatment
  • In vivo CAR-T cells completely eliminated SLE B cells in blood, spleen, and bone marrow of treated mice
  • The tandem CAR-T treatment resulted in effective control of tumors in aggressive B cell lymphoma after a single dose
  • Persistent CAR-T cells may offer a one-time treatment option, potentially eliminating pathogenic B cells.

Cite This Study

Najibi et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdb0a79560c99a0a3eb1https://doi.org/10.1158/1538-7445.am2026-152
View Full Paper
Ask AI
Bookmark
Share